Immune-related iritis and immune-mediate scleritis

Management

• Encourage patient to report an eye symptom immediately
• Obtain ophthalmology referral
• Anticipate ipilimumab holds for any Grade 2 AE; resume when returns to G0 or 1; permanently discontinue for any G3–4 (life-threatening) AE, persistent G2 AE lasting ≥6 weeks, or inability to reduce corticosteroid dose to 7.5 mg/d prednisone or equivalent.